The role of the chief medical social media officer

Amy Baxter | | Health Exec | Management
smartphone

An emergence of fake medical news and untrustworthy medical advice on social media has led to the creation of a new type of role at Jefferson Health, a health system in Pennsylvania and New Jersey.

Austin Chiang, MD, a Harvard-trained gastroenterologist, is leading the charge at the health institute to counter fake news through his role as chief medical social media officer, CNBC reported. His social media presence on Instagram, as GI Doctor, has accumulated 20,000 followers, where he shares images of himself with captions about the latest insights or research and advice to patients to sort through the high amount of medical advice across the internet.

This presence by doctors on social media meets patients and consumers where they are––on Facebook and Instagram. Both these platforms have seen a surge in bad medical advice that has become “the biggest crisis we have right now in healthcare,” Chiang told CNBC.

His social media passion aims to recruit an “army” of physicians, nurses, patient advocates and other healthcare professionals to get online and get good information out there for patients. He has been serving in the role at Jefferson Health since 2018.

See the fully story below:

This doctor is recruiting an army of medical experts to drown out fake health n…

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.